Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biologic high risk Multiple Myeloma:~  * Stage II/III Multiple Myeloma, any of: t(4; 14), t(14; 16),(14:20) by Fish; 17P- by conventional cytogenetics or Fish; ∆13 by conventional cytogenetics; Hypodiploidy by conventional cytogenetics.~    * Relapsed or persistent multiple myeloma after ASCT.~   * Persistent multiple myeloma, regardless of previous therapies.~   * Plasma cell leukemia, regardless of previous therapies.~* Age up to 70 years old (less than 71 years old at the date of transplant admission).~* Disease status: in CR, nCR, VGPR, PR or stable disease within 1 month of admission~* Patients with non-secretory and oligosecretory disease are eligible if they meet certain criteria within 2 weeks prior to the transplant.~* Specific renal, liver, cardiac, and pulmonary function requirements(all must be met within 30 days of transplant admission)~Exclusion Criteria:~* Persistent invasive infections, not controlled by antimicrobials.~* HIV-1/HIV-2 or HTLV-1/HTLV-2 seropositivity.~* Uncontrolled medical or psychiatric disorder.~* No response or progressive disease at the time of transplantation.~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Flu-Bu4 (Type: EXPERIMENTAL): Fludarabine Busulfan chemotherapy regimen(Flu-Bu4), followed by allogeneic stem cell transplant from best available, matched donor.

Based on this trial design, predict the completion outcome and termination type (if applicable).